SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?


To: Haim R. Branisteanu who wrote (183393)2/1/2022 7:14:35 AM
From: THE ANT  Respond to of 218005
 
In particular, the increased dependence of Nf2-deficient cells on lipid synthesis suggests that Fasn inhibitors, alone or in combination with other agents that increase malonyl-CoA levels, might be useful in treating NF2-related diseases.

Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? - PubMed (nih.gov)